OCUGEN, INC. (OCGN) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Current obligations | 133.08M USD | Liabilities, Current |
| Cash and equivalents | 100.05M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $133.08M | $100.05M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $20.71M | $31.90M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $23.04M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $20.36M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $17.99M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $16.89M | $37.80M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $21.59M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $15.76M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $17.97M | $15.70M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $16.05M | $26.38M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $17.09M | $39.46M | $0.00 | (m) | (m) | (m) |
| 2023-09-30 | (m) | $11.14M | $53.48M | $0.00 | (m) | (m) | (m) |
| 2023-06-30 | (m) | $13.46M | $70.58M | $0.00 | (m) | (m) | (m) |
| 2023-03-31 | (m) | $15.68M | $68.26M | $8.46M | (m) | (m) | (m) |
| 2022-12-31 | (m) | $18.46M | $77.56M | $13.37M | (m) | (m) | (m) |
| 2022-09-30 | (m) | $14.91M | $101.60M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $10.34M | $115.00M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $7.69M | $129.77M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $7.00M | $94.96M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $6.23M | $107.35M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $4.84M | $115.64M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $4.28M | $44.79M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $3.61M | $24.04M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $4.13M | $19.11M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $7.04M | $14.97M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $3.31M | $3.19M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $4.54M | $7.44M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $35.41M | $15.30M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $791.00K | $2.79M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $2.32M | $7.38M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.87M | $15.54M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $8.94M | $5.19M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $11.66M | $8.77M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $8.42M | $15.51M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $3.81M | $7.08M | $900.00K | (m) | (m) | (m) |
| 2017-09-30 | (m) | $2.91M | $10.80M | $1.82M | (m) | (m) | (m) |
| 2017-06-30 | (m) | $3.83M | $10.56M | $7.98M | (m) | (m) | (m) |
| 2017-03-31 | (m) | $3.90M | $16.37M | $8.00M | (m) | (m) | (m) |
| 2016-12-31 | (m) | $5.17M | $31.91M | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $7.21M | $37.99M | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $6.72M | $15.93M | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $5.97M | $22.90M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $6.36M | $30.91M | (m) | (m) | (m) | (m) |
| 2015-12-21 | (m) | (m) | $30.91M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $6.69M | $37.72M | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $6.69M | $45.22M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $7.50M | $53.18M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $8.25M | $58.06M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | $3.26M | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | $7.78M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | $3.36M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $8.73M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |